Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo.

@article{Lorenzi2005AminoAE,
  title={Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo.},
  author={Philip L. Lorenzi and Christopher P. Landowski and Xueqin Song and Katherine Z. Borysko and Julie M. Breitenbach and Jae Seung Kim and John M. Hilfinger and Leroy B. Townsend and John C. Drach and Gordon L Amidon},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2005},
  volume={314 2},
  pages={
          883-90
        }
}
2-Bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole (BDCRB) is a potent and selective inhibitor of human cytomegalovirus (HCMV), but it lacks clinical utility due to rapid in vivo metabolism. We hypothesized that amino acid ester prodrugs of BDCRB may enhance both in vitro potency and systemic exposure of BDCRB through evasion of BDCRB-metabolizing enzymes. To this end, eight different amino acid prodrugs of BDCRB were tested for N-glycosidic bond stability, ester bond stability, Caco-2… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

linked cyclic prodrug of a model hexapeptide

SS Good, BS Owens, LB Townsend, JC Drach
  • Pharm Res
  • 1994
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Stereospecific chemical and enzymatic stability of phosphoramidate triester prodrugs of d4T in vitro.

  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2004
VIEW 1 EXCERPT